2m 2m 2m 2m 2m 2m 2m
- $4.2BMarket Cap
- 99.14%1-Year Change
- Diagnostics & ResearchIndustry
Veracyte (VCYT)
Key Performance
More- Earnings Score: 45
- Momentum Score: 99
- True Yield: N/A
- Financial Health Score: 100
Latest Research & News
Healthcare Innovation Accelerates as Four Converging Forces Drive Early Intervention Focus
Healthcare companies are advancing precision medicine through gene therapy, AI diagnostics, and innovative treatments targeting age-related conditions, with several firms making significant breakthroughs in areas like longevity biotechnology and personalized care.
09/25/2025, 9:15 AM • Benzinga
Peers
Statistics
MoreInformation as of 06/22/2026
Company Profile
Veracyte, Inc. operates as a diagnostics company in the United States and internationally. The company offers Afirma Genomic Sequencing Classifier for cancerous thyroid nodules; Decipher Prostate Genomic Classifiers for prostate cancer diagnosis; Decipher Bladder Genomic Classifier for bladder cancer diagnosis; Prosigna Breast Cancer Assay for breast cancer diagnosis; and Percepta Nasal Swab Test for lung cancer diagnosis. It also provides the nCounter analysis system services. The company was formerly known as Calderome, Inc. and changed its name to Veracyte, Inc. in March 2008. Veracyte, Inc. was incorporated in 2006 and is headquartered in South San Francisco, California.
Key Executives
- Marc A. Stapley
- Phillip G. Febbo
- Rebecca Chambers
- John Leite
- Annie McGuire
Current Ownership Distribution
- Institutions1.5B (74.48%)
- Mutual Funds491.5M (25.14%)
- Insiders7.3M (0.37%)
- Other0 (0.00%)